Baudax Bio launched its new, non-opioid pain medication earlier this week, but due to the ongoing coronavirus crisis, the Malvern-based company is relying on non-traditional methods to promote it, writes John George for the Philadelphia Business Journal.

Baudax Bio originally planned to launch Anjeso later this month. However, the pandemic has caused issues with hiring a full sales team and made it impossible to visit potential customers in their offices.

“These are challenging times for everyone involved in the delivery of healthcare in the United States, and the well-being of everyone involved remains our top priority,” said Baudax Bio CEO Gerri Henwood.

She said that the company has retained a core commercial team while Anjeso was under regulatory review. It has been discussing the new medicine with customers using “virtual outreach,” instead of the usual face-to-face meetings.

“We knew there were people who had a familiarity with the product, and we wanted to make it available to them,” said Henwood.

Read more about Baudax Bio in the Philadelphia Business Journal here.

[lp-contribute]